Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm, established in 1972, making it one of the oldest and most experienced players in the life sciences sector. Headquartered in Paris, France, with additional offices in London and Milan, the firm has built a formidable reputation for investing across the entire spectrum of life sciences, from seed and early-stage ventures to growth and later-stage companies. Their investment scope encompasses biotechnology, medical devices, industrial biotechnology, food and agri-tech, and digital health, reflecting a broad commitment to innovation that impacts health and sustainability.

Sofinnova's strategy is characterized by its long-term commitment and hands-on approach, often taking a lead investor role. They are known for identifying disruptive innovations and supporting their portfolio companies through various stages of development, including clinical trials, regulatory approvals, and market commercialization. The firm manages several specialized funds, such as Sofinnova Capital for early-stage biotech, Sofinnova Crossover for late-stage private and public companies, and Sofinnova Industrial Biotech for sustainable solutions. This multi-fund structure allows them to tailor their investment approach to the specific needs and maturity of different life science sub-sectors.

With over five decades of experience, Sofinnova Partners has successfully backed more than 500 companies globally, demonstrating a deep expertise in navigating the complex life sciences landscape. The firm currently manages over €2.5 billion in assets, equivalent to approximately $2.7 billion USD, underscoring its significant financial capacity and influence in the sector. Their track record includes numerous successful exits through IPOs and M&A, contributing significantly to the advancement of medical and scientific innovation. Their typical initial investment for a promising early-stage venture can range from approximately $1.5 million for seed rounds, extending up to $25 million for leading a substantial Series A or B round, reflecting their broad investment mandate.